Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors

• Maximum Tolerated Dose (MTD) of Abraxane [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  To determine the maximum tolerated dose (MTD) of Abraxane weekly days 1, 8, 15 with a carboplatin dose of AUC=6 given on day 1 of a 28 day cycle
• Maximum Tolerated Dose (MTD) of Abraxane given with Carboplatin [ Time Frame: 21 days ] [ Designated as safety issue: No ]
  To determine the MTD of Abraxane given every 3 weeks with carboplatin given on day 1 of a 21 day cycle
• Sequence-dependent toxicity [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  To determine if there is any correlation to toxicity based on the order Abraxane and carboplatin are adminstered

• Maximum tolerated dose of paclitaxel albumin-stabilized nanoparticle formulation given once in week 1 with carboplatin given once in week 1 with treatment repeated every 3 weeks
• Sequence-dependent effects on toxicity and pharmacokinetics
• Maximum tolerated dose of paclitaxel albumin-stabilized nanoparticle formulation given once in weeks 1, 2, and 3 with carboplatin given once in week 1 with treatment repeated every 4 weeks
• Maximum tolerated dose of paclitaxel albumin-stabilized nanoparticle formulation given once in weeks 1 and 2 with carboplatin given once in week 1 with treatment repeated every 3 weeks

RATIONALE: Drugs used in chemotherapy such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving paclitaxel albumin-stabilized nanoparticle formulation together with carboplatin may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects, the best way to give, and the best dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with carboplatin in treating patients with advanced or metastatic solid tumors.

OBJECTIVES:

Primary

• Determine the maximum tolerated dose (MTD) of paclitaxel albumin-stabilized nanoparticle formulation given once weekly for 3 weeks when administered with carboplatin given once every 4 weeks.
• Determine the MTD of paclitaxel albumin-stabilized nanoparticle formulation given once every 3 weeks when administered with carboplatin given once every 3 weeks.
• Determine the MTD of paclitaxel albumin-stabilized nanoparticle formulation given in weeks 1 and 2 when administered with carboplatin given once every 3 weeks.
• Evaluate sequence-dependent effects on toxicity and pharmacokinetics in the combination of paclitaxel albumin-stabilized nanoparticle formulation and carboplatin.

Secondary

• Explore the antitumor activity of paclitaxel albumin-stabilized nanoparticle formulation given once weekly or once every 3 weeks.

OUTLINE: Patients are assigned to 1 of 3 treatment arms.

• Arm I: Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
• Arm II: Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
• Arm III: Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients in arms I and II undergo blood sample collection periodically for pharmacokinetic studies.

After completion of study treatment, patients are followed at 30 days.

• Drug: Carboplatin
  standard dose of area under the curve (AUC) AUC of 6 in all arms
  Other Name: Paraplatin
• Drug: Abraxane
  75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
  Other Name: Paclitaxil
• Drug: Abraxane
  180mg/m2 - 340mg/m2, repeated every 21 days
  Other Name: Paclitaxil
• Drug: Abraxane
  100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
  Other Name: Paclitaxil

• Active Comparator: Weekly Arm
  Carboplatin day 1, abraxane days 1, 8, 15 every 28 day cycle
  Interventions:

  • Drug: Carboplatin
  • Drug: Abraxane
• Experimental: Every 3 week Arm
  Carboplatin day 1, abraxane day 1, every 21 day cycle
  Interventions:

  • Drug: Carboplatin
  • Drug: Abraxane
• Experimental: Arm C
  Carboplatin day 1, abraxane day 1, 8 every 21 day cycle
  Interventions:

  • Drug: Carboplatin
  • Drug: Abraxane

DISEASE CHARACTERISTICS:

Inclusion criteria:

• Histologically or cytologically confirmed solid tumor

  • Advanced or metastatic disease
• Measurable or evaluable disease

• Must meet 1 of the following criteria:

  • Failed a standard therapy
  • Not a candidate for standard therapy
  • Have a disease for which there is no defined standard therapy

Exclusion criteria:

• Symptomatic brain metastases

PATIENT CHARACTERISTICS:

Inclusion criteria:

• ECOG performance status 0-2
• Life expectancy ≥ 8 weeks
• Absolute neutrophil count > 1,500/mm^3
• Platelet count > 100,000/mm^3
• Hemoglobin > 8.0 g/dL
• Total bilirubin normal
• Serum creatinine normal OR creatinine clearance ≥ 60 mL/min
• AST and ALT ≤ 2.5 x upper limit of normal
• Negative pregnancy test

Exclusion criteria:

• Pregnant or lactating
• Prior anaphylactic reaction or severe allergic reaction to paclitaxel and/or docetaxel
• Active infection that requires treatment with antibiotics for > 4 weeks
• Uncontrolled congestive heart failure
• Symptomatic coronary artery disease or heart block
• Myocardial infarction within the past 3 months
• Peripheral neuropathy ≥ grade 2 from any cause

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy, radiotherapy, or any other therapy for malignancy within the past 3 weeks
• No concurrent filgrastim, pegfilgrastim, or sargramostim during the first course of therapy